Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through “pharmaceuticalization” for the best formulation

Elia Bari, Ilaria Ferrarotti, Maria Luisa Torre, Angelo Guido Corsico, Sara Perteghella

Research output: Contribution to journalReview articlepeer-review


Pulmonary acute and chronic diseases, such as chronic obstructive pulmonary disease, pulmonary fibrosis and pulmonary hypertension, are considered to be major health issues worldwide. Cellular therapies with Mesenchymal Stem Cells (MSCs) offer a new therapeutic approach for chronic and acute lung diseases related to their anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties. Such therapeutic effects can be attributed to MSC-secretome, made of free soluble proteins and extracellular vesicles (EVs). This review summarizes the recent findings related to the efficacy and safety of MSC-derived products in pre-clinical models of lung diseases, pointing out the biologically active substances contained into MSC-secretome and their mechanisms involved in tissue regeneration. A perspective view is then provided about the missing steps required for the secretome “pharmaceuticalization” into a high quality, safe and effective medicinal product, as well as the formulation strategies required for EV non-invasive route of administration, such as inhalation.

Original languageEnglish
Pages (from-to)11-24
Number of pages14
JournalJournal of Controlled Release
Publication statusPublished - Sep 10 2019


  • Exosomes
  • Lung regeneration
  • Mesenchymal stem cells
  • Microvesicles
  • Pulmonary administration
  • Secretome

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through “pharmaceuticalization” for the best formulation'. Together they form a unique fingerprint.

Cite this